REGULATION OF GENE-EDITED UNIVERSAL DONOR IMMUNE CELLS

1. INTRODUCTION

Gene-edited universal donor immune cells are immune cells modified through genetic engineering to reduce immune incompatibility and enable their use in multiple recipients. Examples include engineered T cells used in cancer immunotherapy and other allogeneic cellular therapies. Depending on the product, modifications may aim to reduce graft-versus-host disease, limit rejection by the recipient's immune system, or improve therapeutic activity.

Unlike autologous cell therapies, which use a patient's own cells, universal donor products are generally developed for administration to unrelated recipients. Their potential benefits include standardised manufacturing, reduced waiting times, and broader access to advanced treatments. However, genetic modifications can introduce risks such as unintended genomic changes, abnormal cell proliferation, immune dysfunction, infection, and unpredictable long-term effects.

In India, regulation primarily involves the Central Drugs Standard Control Organisation (CDSCO), the New Drugs and Clinical Trials Rules, 2019, applicable biosafety requirements, and ethical review standards. The applicable route depends on the cell type, genetic modification, manufacturing method, intended indication, and proposed clinical use.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

A. Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019

Gene-edited immune-cell products intended for therapeutic use may fall within the regulatory framework for new drugs and cell- or gene-based therapies. Clinical investigations and marketing require the relevant permissions under the applicable statutory framework.

CDSCO publishes guidance for clinical-trial applications involving cell and gene therapeutics. The National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, developed by ICMR, CDSCO, and DBT, provide an important framework for product development, clinical investigation, and safety evaluation. <Cite refs={["turn428928search4","turn428928search5"]}/>

B. Biosafety regulation

The Environment (Protection) Act, 1986, and the Rules of 1989 governing relevant genetically engineered organisms or cells may apply to aspects of research, handling, and manufacture, depending on the activity and regulatory classification. Institutional Biosafety Committees and the Review Committee on Genetic Manipulation provide oversight within their respective mandates.

C. Ethics and informed consent

Clinical studies must comply with applicable ethical-review requirements, including Institutional Ethics Committee review and informed consent. Participants should receive clear information about the investigational nature of the therapy, potential benefits, foreseeable risks, alternatives, and arrangements for monitoring and treatment of complications.

D. Manufacturing and quality control

Manufacturers must establish appropriate controls over donor eligibility, cell identity, purity, potency, viability, sterility, genomic integrity, and batch consistency. The product's intended use and applicable regulatory requirements determine the precise testing and quality standards.

3. PRINCIPAL REGULATORY REQUIREMENTS

A. Preclinical safety assessment: Developers should assess immune compatibility, unintended editing, genomic instability, abnormal proliferation, and the possibility of harmful immune reactions before proceeding to human trials.

B. Prevention of graft-versus-host disease: Where donor T cells are used, the product's design and safety evaluation should address the possibility that donor cells may attack the recipient's healthy tissues. Reduced incompatibility does not establish universal safety.

C. Prevention of immune rejection: Modifications intended to avoid recognition by the recipient's immune system must be assessed for their effects on immune surveillance, infection susceptibility, and the ability to detect abnormal cells.

D. Clinical-trial authorisation: Human studies must receive the required regulatory permissions and ethical approval. Investigators must comply with the approved protocol, adverse-event reporting obligations, and applicable trial-monitoring requirements.

E. Long-term follow-up: Depending on the product and its risks, follow-up may need to evaluate persistence of modified cells, delayed toxicity, secondary malignancies, immune dysfunction, and other late effects.

F. Post-market surveillance: Once a product is authorised, the responsible manufacturer and healthcare providers must comply with applicable pharmacovigilance, quality-control, and adverse-event reporting requirements.

4. IMPORTANT CASE LAWS

The following Indian judgments establish principles relevant to the regulation of gene-edited immune-cell therapies. They are analogous authorities, not decisions specifically approving or prohibiting universal donor immune cells.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), (2017) 10 SCC 1 — Direct constitutional authority on privacy.

The Supreme Court recognised privacy as a fundamental right protected by the Constitution, including informational privacy and individual autonomy.

Relevance: Collection and use of donor genetic information must respect applicable privacy and data-protection requirements. Genetic testing, storage of genomic records, and sharing information with researchers should have a lawful basis and appropriate safeguards.

2. Samira Kohli v. Dr. Prabha Manchanda (2008), (2008) 2 SCC 1 — Direct medical-consent authority.

The Supreme Court explained the requirements of valid informed consent for medical treatment. Consent to one procedure does not automatically authorise a substantially different procedure, subject to the recognised exceptions.

Relevance: Participants in trials of gene-edited immune cells should receive adequate information about the experimental intervention, material risks, available alternatives, and foreseeable consequences. Consent must be obtained in accordance with applicable law and ethical standards.

3. Jacob Mathew v. State of Punjab (2005), (2005) 6 SCC 1 — Analogous medical-negligence authority.

The Supreme Court examined the principles governing medical negligence and the standard of care expected of medical professionals.

Relevance: Healthcare professionals administering gene-edited cellular therapies must comply with appropriate professional standards, product instructions, and applicable clinical protocols. Whether negligence exists depends on the facts, applicable standard of care, and evidence.

4. Vellore Citizens’ Welfare Forum v. Union of India (1996), (1996) 5 SCC 647 — Analogous precautionary-principle authority.

The Supreme Court recognised the precautionary principle and polluter-pays principle as important components of Indian environmental law.

Relevance: The precautionary principle supports careful assessment of uncertain risks in biotechnology regulation. Its application to a particular cell therapy depends on the environmental or other legal issues involved; it does not independently establish a specific clinical approval requirement.

5. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999), (1999) 2 SCC 718 — Analogous scientific-risk authority.

The Supreme Court highlighted the importance of scientific expertise in decisions involving technical uncertainty and environmental risk.

Relevance: Regulators evaluating gene-edited immune-cell products should rely on competent scientific review, reliable evidence, and appropriate risk assessment. The case supports expert decision-making by analogy, rather than prescribing a particular genomic-testing protocol.

6. Common Cause v. Union of India (2018), (2018) 5 SCC 1 — Analogous autonomy and medical-decision authority.

The Supreme Court addressed dignity, autonomy, and end-of-life medical decision-making, including the legal recognition of advance directives under specified conditions.

Relevance: The judgment reinforces the importance of individual autonomy in medical decision-making. Its relevance to investigational cell therapy is limited to broader principles of dignity and autonomy; clinical-trial consent must principally be assessed under the applicable drug-trial and ethics framework.

5. PRACTICAL COMPLIANCE MEASURES

Developers, manufacturers, and clinical institutions should implement the following measures:

Regulatory classification: Confirm the product's classification and obtain all required permissions from CDSCO and other competent authorities.

Donor screening: Apply appropriate donor eligibility, infectious-disease screening, and traceability procedures.

Genomic quality control: Establish validated testing for identity, editing outcomes, unintended genomic changes, and relevant product-specific risks.

Manufacturing controls: Maintain appropriate manufacturing standards, batch records, chain of identity, chain of custody, and release criteria.

Ethical safeguards: Obtain informed consent, secure ethics approval, protect personal and genetic information, and maintain independent oversight.

Clinical safety monitoring: Establish procedures for recognising and reporting severe immune reactions, infections, abnormal cell proliferation, and other adverse events.

Long-term accountability: Maintain appropriate follow-up, pharmacovigilance, and procedures for managing delayed complications.

6. CONCLUSION

Gene-edited universal donor immune cells represent an important development in advanced cellular medicine, but their allogeneic nature and genetic modifications require careful safety assessment and regulatory oversight. India's framework combines drug regulation, biosafety requirements, clinical-trial ethics, and professional responsibilities. The judgments in Puttaswamy, Samira Kohli, and Jacob Mathew provide important principles concerning privacy, informed consent, and medical standards, while environmental and scientific-risk cases offer more limited analogous guidance.

The central regulatory objective is to ensure that these therapies are developed and administered through lawful authorisation, rigorous quality controls, informed participation, and appropriate short- and long-term safety monitoring.

Current regulatory note: India's published framework includes the National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, and CDSCO's guidance for clinical-trial applications involving cell and gene therapeutics. The precise approval pathway must be confirmed for the particular product and intended use.